[Transferability of clinical trials results into clinical practice: examples taken from cardiology].
A prospective and randomized trial design is of utmost interest when it comes to evaluating new developments in the management of cardiovascular medicine. By defining the primary end point and a profound related statistic new therapeutic options can be tested with an adequate number of patients. The course of the trial is supervised by a Clinical Events Committee and a Data and Safety Monitoring Board. Registries are promising tools for describing how the results of clinical trials are translated into daily practice. Their drawbacks include lack of control of the clinical endpoints and their uniform definition and lack of a control group. There are numerous examples from cardiology of the limited usefulness of data obtained from registry studies with their often unexpected results that might have significant but unsubstantiated implications for the provision of care to cardiac patients.
Rutsch
Wolfgang
W
Medizinische Klinik und Poliklinik, Schwerpunkt Kardiologie und Angiologie, Charité, Universitätsmedizin Berlin, Campus Mitte. wolfgang.rutsch@helios-kliniken.de
D002309:Cardiology / Q000379:methods / Q000592:standards*; D002986:Clinical Trials as Topic / Q000592:standards*; D054855:Drug-Eluting Stents / Q000009:adverse effects / Q000706:statistics & numerical data; D006801:Humans; D015425:Myocardial Reperfusion / Q000706:statistics & numerical data*; D012107:Research Design / Q000592:standards